Reported resolution of skin injuries in all 12 patients.
StrataCTX · Clinical evidence
Clinical evidence
Explore the reported clinical experience with StrataCTX.
Clinical results
Medical Adhesive-Related Skin Injuries
Paediatric oncology supportive care
The case series
A case series with 12 paediatric patients at Children’s Health Queensland Hospital and Health Service, Australia, described the use of StrataCTX for MARSI secondary to central venous access device dressings.12
Reported findings
- Skin injuries resolved in all patients within 14 days or less.
- StrataCTX helped maintain a moist, semi-permeable environment without causing abrasion or irritation.
- Patients and caregivers reported less pruritus and irritation.
StrataCTX forms a flexible dressing which lightly bonds to the contours of the skin, providing full contact with the affected area.
Case 1
Case 2
02 / Cubiro 2018
Cutaneous reaction following topical imiquimod13
An 82-year-old man developed an intense inflammatory reaction on the scalp after treatment of actinic keratoses with imiquimod.
Local inflammation on the scalp persisted, causing significant pain and social isolation for the patient.
Results
- After 2 weeks of treatment with StrataCTX, there was a major improvement in the epithelialisation of all ulcerated areas, with minimal superficial scabs.
- StrataCTX showed efficacy in preventing the manifestation of abnormal scarring.
Research in focus
White papers
01 Cutaneous T-Cell Lymphoma (CTCL)
01 / StrataCTX English · PDF
StrataCTX as a steroid-sparing supportive therapy for CTCL-induced pruritus
A summary of the interim analysis reported by Lapolla, Geskin and colleagues in 2024, examining topical steroid use, itch severity and quality of life after one month of StrataCTX in patients with cutaneous T-cell lymphoma.
